Corrigendum to: Thinking ahead: developing biosynthetic blood to anticipate donor drought
Cell & Gene Therapy Insights 2023; 9(1), 51–52
10.18609/cgti.2023.007
This corrigendum contains corrections the following article:
Thinking ahead: developing biosynthetic blood to anticipate donor drought Cell & Gene Therapy Insights 2022; 8(11), 1561–1570; DOI: 10.18609/cgti.2022.227.
In the version of this article initially published, it was stated that clinical trials for Hemarina M101 had been suspended. In fact, at the time of publication, Hemarina’s HEMO2life® had just received CE approval for the preservation of kidney grafts for transplantation. The correction is listed in full below, and the amended article can be accessed here.
In the version of this article initially published, it was incorrectly stated that trials for Hemarina M101 had been suspended. The paragraph with the corrected information is below:
Unfortunately, further development has been stifled by insufficient funding. Federal agencies have focused funding for decades on artificial (synthetic) blood substitutes based on purified forms of hemoglobin to provide oxygen carrying capacity in acute blood loss situations [23]. Despite some advances, no synthetic blood substitutes are approved for use in the US or Europe. Significant safety issues and high mortality [24], including myocardial infarction and death, have been associated with the use of these artificial blood products [24]. Some synthetic products such as Erythromer [25] are still proceeding through early-stage development. In a first for the category of oxygen carriers Hemarina’s HEMO2life® just received CE approval for preservation of kidney grafts for transplantation [26]. And while a retrospective study of ten patients showed one artificial blood product to provide an effective oxygen bridge for patients unable to be transfused with RBC [27], other case reports illustrate the significant challenges with use of artificial blood [28].
Furthermore, reference 26, has been corrected to:
26. Hemarina. The European Union recognizes the first universal oxygen carrier. Press release. Sep 30 2022 https://www.hemarina.com/the-european-union-recognizes-the-first-universal-oxygen-carrier/?lang=en.